2.50
Hdl Handle:
http://hdl.handle.net/10541/70331
Title:
Antiangiogenic therapy for ovarian cancer.
Authors:
Rosa, Daniela D; Clamp, Andrew R; Collinson, Fiona J; Jayson, Gordon C ( 0000-0002-8515-8944 )
Abstract:
PURPOSE OF REVIEW: To highlight the current antiangiogenic compounds being evaluated as single agents or in association with chemotherapy in the treatment of ovarian cancer, as well as the rationale for their development. RECENT FINDINGS: Several proangiogenic factors may be potential targets for antiangiogenic therapy in ovarian cancer. Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been evaluated as a single agent in two phase II clinical trials and in combination with chemotherapy in three phase II studies, with promising results. This agent is also being evaluated in association with chemotherapy in two phase III clinical trials, both in the treatment and in the maintenance settings. Heparanase inhibitors and inhibitors of platelet-derived growth factor signalling remain as potential agents to be investigated in phase II trials. The development of biomarkers to define appropriate dosing regimens and predict which patients may benefit from antiangiogenic therapies is of great importance. SUMMARY: Data from preclinical and clinical studies reported in the last 2 years demonstrate the importance of several proangiogenic factors in the prognosis of ovarian cancer, suggesting possible new targets for antiangiogenic therapy. The agents that are currently being investigated in phase II and III clinical trials include bevacizumab, erlotinib, sunitinib, sorafenib and vascular endothelial growth factor Trap, and the results of these trials will have significant implications in the future management of ovarian cancer.
Affiliation:
Cancer Research UK and University of Manchester, Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK.
Citation:
Antiangiogenic therapy for ovarian cancer. 2007, 19 (5):497-505 Curr Opin Oncol
Journal:
Current Opinion In Oncology
Issue Date:
Sep-2007
URI:
http://hdl.handle.net/10541/70331
DOI:
10.1097/CCO.0b013e32827035f0
PubMed ID:
17762578
Type:
Article
Language:
en
ISSN:
1040-8746
Appears in Collections:
All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorRosa, Daniela D-
dc.contributor.authorClamp, Andrew R-
dc.contributor.authorCollinson, Fiona J-
dc.contributor.authorJayson, Gordon C-
dc.date.accessioned2009-06-12T14:41:40Z-
dc.date.available2009-06-12T14:41:40Z-
dc.date.issued2007-09-
dc.identifier.citationAntiangiogenic therapy for ovarian cancer. 2007, 19 (5):497-505 Curr Opin Oncolen
dc.identifier.issn1040-8746-
dc.identifier.pmid17762578-
dc.identifier.doi10.1097/CCO.0b013e32827035f0-
dc.identifier.urihttp://hdl.handle.net/10541/70331-
dc.description.abstractPURPOSE OF REVIEW: To highlight the current antiangiogenic compounds being evaluated as single agents or in association with chemotherapy in the treatment of ovarian cancer, as well as the rationale for their development. RECENT FINDINGS: Several proangiogenic factors may be potential targets for antiangiogenic therapy in ovarian cancer. Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been evaluated as a single agent in two phase II clinical trials and in combination with chemotherapy in three phase II studies, with promising results. This agent is also being evaluated in association with chemotherapy in two phase III clinical trials, both in the treatment and in the maintenance settings. Heparanase inhibitors and inhibitors of platelet-derived growth factor signalling remain as potential agents to be investigated in phase II trials. The development of biomarkers to define appropriate dosing regimens and predict which patients may benefit from antiangiogenic therapies is of great importance. SUMMARY: Data from preclinical and clinical studies reported in the last 2 years demonstrate the importance of several proangiogenic factors in the prognosis of ovarian cancer, suggesting possible new targets for antiangiogenic therapy. The agents that are currently being investigated in phase II and III clinical trials include bevacizumab, erlotinib, sunitinib, sorafenib and vascular endothelial growth factor Trap, and the results of these trials will have significant implications in the future management of ovarian cancer.en
dc.language.isoenen
dc.subjectOvarian Canceren
dc.subject.meshAngiogenesis Inhibitors-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshOvarian Neoplasms-
dc.titleAntiangiogenic therapy for ovarian cancer.en
dc.typeArticleen
dc.contributor.departmentCancer Research UK and University of Manchester, Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK.en
dc.identifier.journalCurrent Opinion In Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.